Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

Purpose

Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly suspect cases) among healthcare workers (HCW) within the Montefiore Health System (MHS), hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk for severe COVID19 illness.

Conditions

  • COVID
  • Coronavirus
  • COVID-19

Eligibility

Eligible Ages
Between 18 Years and 99 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Symptomatic with COVID illness (either RT-PCR test confirmed or highly suspect clinical symptoms) - Call into office within the first 7 days of illness - Have any of the following high risk conditions: - Age >60 - HTN, CAD, or chronic heart disease - Diabetes - Chronic kidney disease - Chronic lung disease - Active or recent chemotherapy for malignancy - Organ transplant - Taking Immune-suppressing medications - HIV with CD4 <200 cells/mm3 - Experiencing at least one of the following high risk symptoms: - Severe cough - Fever 100.0F or greater - Diarrhea - Shortness of Breath - Hypoxia

Exclusion Criteria

• HCW not meeting high-risk criteria or those with a contraindication to HCQ will not be offered HCQ

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Treatment Group 		Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study
  • Drug: Hydroxychloroquine
    400 mg tablet
No Intervention
Control Group 		Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms

Recruiting Locations

More Details

NCT ID
NCT04350450
Status
Withdrawn
Sponsor
Montefiore Medical Center